Listen Now
Topics Covered
- Overview of HER2 Low Breast Cancer
- What is the HER2 Status of My Cancer? What does this Mean?
- Diagnostic Testing: What is an Immunohistochemistry (IHC) Test or Fluorescence In Situ Hybridization (FISH) Test
- The Role of the Pathologist
- The Role of the Genetic Counselor
- Standard Treatment Options, Including Targeted Therapy
- How Biomarker Testing Informs Treatment Decisions
- New Targeted Treatments
- Updates on Investigational New Drugs in Clinical Trials
- How Research Contributes to Treatment Options
- What’s New in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain
- The Role of the Dietitian
- Guidelines to Prepare for Telemedicine/Telehealth Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes
- Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns for HER2 Low Breast Cancer
- Questions for Our Panel of Experts
Our Panel of Experts

Paolo Tarantino, MD, PhD
Breast Medical Oncologist, Clinical Researcher, Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School

Kamel Abou Hussein, MD
Assistant Professor of Medicine, Cooper Medical School of Rowan University, Adjunct Assistant Professor, Department of Breast Medical Oncology, MD Anderson Cancer Center, Co-Director of the Janet Knowles Breast Cancer Program, Director of Breast Cancer Clinical Trials, MD Anderson Cancer Center at Cooper

Mara H. Rendi, MD, PhD
Pathologist specializing in Breast Cancer, Abbott Northwestern Hospital, Hospital Pathology Associates and Allina Health, Minneapolis, Minnesota

Kara R. (Schoeffel) Rogen, MS, CGC
Licensed Certified Genetic Counselor, Department of Clinical Genomics, Mayo Clinic

Diana L. Bearden, MS, RD, CSO, LD, CNSC
Oncology Dietitian, Michael E. DeBakey VA Medical Center

Cassie Spector, MSW, OSW-C
Breast and Gynecological Cancers Program Coordinator, CancerCare
Brochure
You can download the brochure for this workshop
Workshop Date
This workshop was originally recorded on April 29, 2025.